Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson’s disease model

Therapeutics designed to target α-synuclein (α-syn) aggregation may be critical in halting the progression of pathology in Parkinson’s disease (PD) patients. Nanobodies are single-domain antibody fragments that bind with antibody specificity, but allow readier genetic engineering and delivery. When...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatterjee, Diptaman, Bhatt, Mansi, Butler, David, De Genst, Erwin, Dobson, Christopher M., Messer, Anne, Kordower, Jeffrey H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105584/
https://www.ncbi.nlm.nih.gov/pubmed/30155513
http://dx.doi.org/10.1038/s41531-018-0062-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105584/
https://www.ncbi.nlm.nih.gov/pubmed/30155513
http://dx.doi.org/10.1038/s41531-018-0062-4

Ejemplares similares